|
| Vaccine name | Approval date | Valency | Description | Manufacture and marketing |
|
b-CAPSA 1
Hib-VAX
Hib-IMUNE | 1985 US | Monovalent | Pure polysaccharide CPS vaccine (unconjugated). The vaccine was recommended routinely for children at 24 months of age and for children at 15 months of age enrolled in child care facilities. The vaccine was not consistently immunogenic in children <18 months of age and was withdrawn from the market in 1988. | b-CAPSA 1 by Praxis, Biologics, Hib-VAX by Connaught, and Hib-IMUNE by Lederle |
|
| ProHIBIT | 1987 US | Monovalent | First conjugate Haemophilusinfluenzae b vaccine to be approved by FDA. ProHIBIT is no longer available in the United States. | Connaught Laboratories, Inc. |
|
| HibTITER | 1990 US | Monovalent | Hib conjugate vaccine (diphtheria CRM197 protein conjugate). Discontinued 2007. | Wyeth Pharmaceuticals Inc. |
|
| PedvaxHIB | 1989 US | Monovalent | Hib conjugate vaccine (meningococcal protein conjugate). | Merck & Co., Inc.
http://www.merck.com/product/vaccines/home.html |
|
| ActHIB | 1993 US | Monovalent | Approved for use as a four-dose series in infants and children 2 months through 5 years of age. | Sanofi Pasteur
http://www.sanofipasteur.com/en/ |
|
| OmniHib | 1993 US | Monovalent | Hib conjugate vaccine. No longer available in the United States. | SmithKline Beecham |
|
| TriHIBit | 1996 US | Polyvalent | Combination of DTaP and Hib vaccine, licensed for the fourth dose in the DTaP and Hib series. Discontinued on 2011 according to CDC. | Sanofi Pasteur
http://www.sanofipasteur.com/en/ |
|
| Comvax | 1996 US | Polyvalent | Mixed vaccines of recombinant hepatitis B antigen and Haemophilusinfluenzae type b conjugated vaccine. Discontinued on 2014 according to Merck. | Merck & Co., Inc.
http://www.merck.com/product/vaccines/home.html |
|
| Tetramune | 1996 US | Polyvalent | DTP and Hib conjugate vaccine. Discontinued according to CDC. | Wyeth Pharmaceuticals Inc. |
|
| PROCOMVAX | 1999 EU | Polyvalent | Hib conjugate and hepatitis B (recombinant) vaccine. Withdrawn on 2009 according to EMA. | Sanofi Pasteur MSD
http://www.spmsd.com/ |
|
| Hexavac | 2000 EU | Polyvalent | Diphtheria, tetanus, acellular pertussis, inactivated poliomyelitis, hepatitis B (recombinant), and Hib conjugate vaccine, adjuvant. Suspended 2005, withdrawn on 2012 according to EMA. | Sanofi Pasteur
http://www.sanofipasteur.com/en/ |
|
| Infanrix-Hib | 2000 EU
2002 US | Polyvalent | DTaP and adsorbed conjugated
Hib vaccine. | GlaxoSmithKline Biologicals
https://www.gsk.com/ |
|
| Infanrix Hexa | 2000 EU | Polyvalent | DTaP, hepatitis B (recombinant), inactivated poliomyelitis, and adsorbed conjugated Hib vaccine. | GlaxoSmithKline Biologicals
https://www.gsk.com/ |
|
| Quintanrix | 2005 EU | Polyvalent | DTP, hepatitis B (rDNA), and adsorbed Hib conjugate vaccine. Withdrawn on 2008 according to EMA. | GlaxoSmithKline Biologicals
https://www.gsk.com/ |
|
| Pentacel | 2008 US | Polyvalent | DTaP adsorbed, inactivated poliovirus, and Hib conjugate. | Sanofi Pasteur
http://www.sanofipasteur.com/en/ |
|
| Hiberix | 2009 US | Monovalent | Hib conjugate vaccine (tetanus toxoid conjugate). Approved only as a booster dose of the Hib schedule among children 12 months and older. | GlaxoSmithKline Biologicals
https://www.gsk.com/ |
|
| MenHibrix | 2012 US | Polyvalent | Meningococcal groups C and Y and Hib tetanus toxoid conjugate vaccine for infants at increased risk of meningococcal disease. | GlaxoSmithKline Biologicals
https://www.gsk.com/ |
|
| Hexacima | 2013 EU | Polyvalent | DTaP, hepatitis B (rDNA), poliomyelitis (inactivated), and adsorbed Hib conjugate vaccine. | Sanofi Pasteur
http://www.sanofipasteur.com/en/ |
|
| Hexyon | 2013 EU | Polyvalent | DTaP, hepatitis B (rDNA), inactivated poliomyelitis, and Hib conjugate vaccine (adsorbed). | Sanofi Pasteur
http://www.sanofipasteur.com/en/ |
|
| INFANRIX-IPV/Hib | 2015 US | Polyvalent | DTaP, inactivated poliomyelitis, and Hib vaccine. | GlaxoSmithKline Biologicals
https://www.gsk.com/ |
|
